Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study ; volume:7 ; number:1 ; day:3 ; month:12 ; year:2019 ; pages:1-12 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (3.12.2019), 1-12, 12.2019
- Urheber
-
Manson, Guillaume
Maria, Alexandre Thibault Jacques
Poizeau, Florence
Danlos, François-Xavier
Kostine, Marie
Brosseau, Solenn
Aspeslagh, Sandrine
Rusquec, Pauline Du
Roger, Maxime
Pallix-Guyot, Maud
Ruivard, Marc
Dousset, Léa
Grignou, Laurianne
Psimaras, Dimitri
Pluvy, Johan
Quéré, Gilles
Grados, Franck
Duval, Fanny
Bourdain, Frederic
Maigne, Gwenola
Perrin, Julie
Godbert, Benoit
Taifas, Beatris Irina
Forestier, Alexandra
Voisin, Anne-Laure
Martin-Romano, Patricia
Baldini, Capucine
Marabelle, Aurélien
Massard, Christophe
Honnorat, Jérôme
Lambotte, Olivier
Michot, Jean-Marie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0821-8
- URN
-
urn:nbn:de:101:1-2020032622163159150951
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Manson, Guillaume
- Maria, Alexandre Thibault Jacques
- Poizeau, Florence
- Danlos, François-Xavier
- Kostine, Marie
- Brosseau, Solenn
- Aspeslagh, Sandrine
- Rusquec, Pauline Du
- Roger, Maxime
- Pallix-Guyot, Maud
- Ruivard, Marc
- Dousset, Léa
- Grignou, Laurianne
- Psimaras, Dimitri
- Pluvy, Johan
- Quéré, Gilles
- Grados, Franck
- Duval, Fanny
- Bourdain, Frederic
- Maigne, Gwenola
- Perrin, Julie
- Godbert, Benoit
- Taifas, Beatris Irina
- Forestier, Alexandra
- Voisin, Anne-Laure
- Martin-Romano, Patricia
- Baldini, Capucine
- Marabelle, Aurélien
- Massard, Christophe
- Honnorat, Jérôme
- Lambotte, Olivier
- Michot, Jean-Marie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Cancer immunotherapies targeting the PD-1 signaling pathway
Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Cancer immunotherapies targeting the PD-1 signaling pathway
Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Cancer immunotherapies targeting the PD-1 signaling pathway
Correction to: Efficacy and safety of anti‑PD‑1/PD‑L1‑based dual immunotherapies versus PD‑1/PD‑L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta‑analysis
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody